Biomerica, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09061H3075
USD
2.30
0 (0.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Biomerica, Inc. stock-summary
stock-summary
Biomerica, Inc.
Pharmaceuticals & Biotechnology
Biomerica, Inc. is a biomedical company, which develops, manufactures, and markets medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The medical diagnostic products are sold in two markets: clinical laboratories and point of care. The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Biomerica has developed a diagnostic guided therapy that is designed to allow physicians to identify patient-specific foods, that when removed from the diet, may alleviate or improve an individual's symptoms of Irritable Bowel Syndrome (IBS). This product is called InFoods IBS.
Company Coordinates stock-summary
Company Details
17571 von Karman Ave , IRVINE CA : 92614-6207
stock-summary
Tel: 1 949 6452111
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (4.62%)

Foreign Institutions

Held by 3 Foreign Institutions (0.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Zackary Irani
Chairman of the Board, Chief Executive Officer
Mr. Allen Barbieri
Lead Independent Executive Vice Chairman of the Board, Corporate Secretary
Dr. Francis Cano
Independent Director
Ms. Catherine Coste
Independent Director
Dr. Jane Emerson
Independent Director
Dr. Mark Sirgo
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - May 2025)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.50

stock-summary
Return on Equity

-121.14%

stock-summary
Price to Book

2.00